Double hemispheric Microdialysis study in poor-grade SAH patients by Torné, Ramón et al.
1Scientific RepoRtS |         (2020) 10:7466  | https://doi.org/10.1038/s41598-020-64543-x
www.nature.com/scientificreports
Double hemispheric Microdialysis 
study in poor-grade SAH patients
Ramon torné1 ✉, Diego culebras1, Gerard Sanchez-etayo2, Sergio García-García1,3 ✉, 
Guido Muñoz2, Laura Llull4, Sergio Amaro4, christian Heering2, Jordi Blasco5, 
elizabeth Zavala2 & Joaquim enseñat1
Delayed cerebral ischemia (DCI) is a dreadful complication present in 30% of subarachnoid hemorrhage 
(SAH) patients. Dci prediction and prevention are burdensome in poor grade SAH patients (WfnS 
4–5). Therefore, defining an optimal neuromonitoring strategy might be cumbersome. Cerebral 
microdialysis (CMD) offers near-real-time regional metabolic data of the surrounding brain. However, 
unilateral neuromonitoring strategies obviate the diffuse repercussions of SAH. To assess the utility, 
indications and therapeutic implications of bilateral cMD in poor grade SAH patients. poor grade SAH 
patients eligible for multimodal neuromonitoring were prospectively collected. Aneurysm location 
and blood volume were assessed on initial Angio-CT scans. CMD probes were bilaterally implanted and 
maintained, at least, for 48 hours (h). Ischemic events were defined as a Lactate/Pyruvate ratio >40 and 
Glucose concentration <0.7 mmol/L. 16 patients were monitored for 1725 h, observing ischemic events 
during 260 h (15.1%). Simultaneous bilateral ischemic events were rare (5 h, 1.9%). The established 
threshold of ≥7 ischemic events displayed a specificity and sensitivity for DCI of 96.2% and 83.3%, 
respectively. Bilateral CMD is a safe and useful strategy to evaluate areas at risk of suffering DCI in SAH 
patients. Metabolic crises occur bilaterally but rarely simultaneously. Hence, unilateral neuromonitoring 
strategies underestimate the risk of infarction and the possibility to offset its consequences.
Delayed cerebral ischemia (DCI) is considered one of the main causes of neurological deficits in subarachnoid 
hemorrhage (SAH) and it may occur in up to 30% of patients. DCI typically occurs between the fourth and tenth 
day after bleeding but its pathophysiology remains yet unclear. Nevertheless, various pathological phenomena 
such as oxidative stress, cortical spreading depolarizations, microvascular thrombosis and disbalances in cerebral 
microcirculation are known to be involved in its development1,2. On the other hand, the role of vasospasm in DCI 
appearance is nowadays controversial. In fact, angiographic vasospasm resolution induced by novel therapies 
such as clazosentan, does not correlate neither with DCI prevention nor with functional prognosis3. This fact may 
support the absence of a causal relationship between vasospasm and DCI4,5.
In poor grade SAH patients, CMD monitoring may be useful for early detection of potentially salvageable 
brain tissue exposed to ischemic risk. CMD monitoring provides semiquantitative metabolic measurements of 
the brain tissue independently of the initial insult. CMD patterns of ischemia (Glucose <0.7 mmol/l and Lactate 
pyruvate ratio (LPR) > 40) have been consistently associated with high specificity and sensitivity to detect 
DCI4,6,7. However, CMD requires a small surgery, its cost is not despicable and the locally confined nature of the 
obtained measurements limits their validity to interpret the global state of the brain. One of the major challenges 
when dealing with CMD is to extrapolate the local and timely delayed measurements it provides. Therefore, 
determining the location of the catheters is not a trivial issue. CMD catheters are normally placed in the frontal 
lobe, in the watershed area between the vascular territories of the middle and anterior cerebral arteries (MCA 
and ACA). In SAH patients, the catheter is consensually placed in the hemisphere where the aneurysm or most 
of the blood are located. Nevertheless, ischemic events in non-monitored areas will probably be disregarded. 
Furthermore, it might be difficult to determine which hemisphere is at risk in some ACA aneurysms or diffuse 
bleeding patterns. Ischemia in the non-monitored hemisphere is not rare and it may represent up to one third of 
secondary infarctions8,9.
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Using a “one catheter” monitoring protocol means assuming that the hemisphere hosting more blood is the 
most susceptible and that information from one side might be extrapolated to identify metabolic changes in 
remote areas. However, regarding SAH, there is a lack of knowledge on the frequency of silent infarcts and the 
metabolic response of those contralateral areas to the primary insult. Thus, in the present clinical investigation we 
sought to assess the utility of a bilateral CMD monitoring protocol in the setting of poor grade SAH patients. Our 
main objective was to detect bilateral metabolic ischemic events in order to identify silent infarcts. This informa-
tion may contribute to anticipate DCI diagnosis and may also provide us with therapeutic tools to prevent this 
feared complication.
Methodology
All methods were carried out in accordance with relevant guidelines and regulations. The methodology of 
this report follows the recommendations of the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) guidelines10.
The present research was approved by the institutional review board (Comité ético de investigaciones clínicas 
del Hospital Clínic de Barcelona. CEIC-Reference number HCB/2018/0390). Moreover, in the absence of con-
scious patients, first grade relatives signed an informed consent authorizing patient’s inclusion in the bilateral 
CMD neuromonitoring protocol.
patients. Poor grade SAH patients (WFNS 4 or 5 grades) eligible for multimodal neuromonitoring were 
prospectively collected between January 2017 and January 2019. Included patients were those whose neurological 
status required maintaining them under sedation and ventilation for at least 48 hours. Patients who survived less 
than 24 h or in whom CMD monitoring lasted less than 48 h were excluded.
Management. CMD catheters were implanted bilaterally in MCA/ACA watershed territory just after the 
surgical or endovascular exclusion of the aneurysm. Aneurysm exclusion modality was decided consensually by 
our neurovascular board. CMD catheters were implanted in the operating room using a mini burr hole located at 
Kocher’s point. In patients with surgically treated aneurysms, ipsilateral CMD catheter was placed under direct 
vision through a small corticectomy. A computed tomography (CT) was performed in the 24 hours following 
CMD catheters placement to confirm their correct location and to rule out early ischemic lesions due to aneu-
rysm exclusion or as a response to SAH primary insult.
Microdialysis monitoring. Cerebral microdialysis was performed using a 20 kDa catheter (CMA 70; CMA/
Microdialysis, Solna, Sweden) with a membrane length of 10 mm. The intraparenchymal probe was implanted at 
a depth of 2–3 cm and connected to the perfusion pump (CMA 106; CMA/Microdialysis). Perfusion fluid (CMA 
T [CMA/Microdialysis], consisting of Na+ 147 mmol/L, K+ 4 mmol/L, Cl 156 mmol/L, pH 6, osmolality 290 
mosm/kg) was pumped at a flow rate of 0.3 μl/minute. Conventional microdialysis analysis equipment (CMA 600; 
CMA/Microdialysis) was implemented to record extracellular fluid concentrations of glucose, pyruvate, lactate, 
glycerol, and glutamate11.
Samples were collected hourly. Data recording was stopped if one or both catheters consistently reported 
errors. Ischemic events were defined as those observations in which Lactate/Piruvate ratio (LPR) was >40 and 
Glucose concentration was <0.7 mmol/L.
All monitored patients underwent a safety protocol in order to spot any issues related to such monitoring. The 
safety protocol included: (1) Daily revision of catheter wounds to identify any CSF leak or purulent material; (2) 
Once the monitoring was over, the catheter tip was routinely sent to the lab for culture; (3) A CT scan was rou-
tinely performed after catheter placement in order to rule out hematomas -any blood collection over 5cc- or any 
other complication related to the catheter insertion.
cerebral blood volumetry and aneurysm location. Cerebral blood volumetry in the initial CT was cal-
culated using OSIRIX12. Aneurysm’s parent vessel and hemisphere were defined on the AngioCT. The CMD probe 
located in the hemisphere containing more blood was named “a”, while “b” was reserved for the contralateral one. 
In those cases, in which differences in volumetry between hemispheres were inferior to 5cc, “a” was used for the 
catheter ipsilateral to the aneurysm (Fig. 1). Anterior communicating artery (AcoA) aneurysms were considered 
left or right depending on the dominant A1 segment.
cerebral magnetic resonance (Dci). Cerebral magnetic resonance (MRI) was performed prior to 
patient’s discharge and within 14 days of SAH. This MRI was aimed to find new ischemic lesions not present in 
the initial CT. Ischemic lesions were classified into two categories: those happening in the brain tissue typically 
considered at risk and those occurring in silent areas. It was also determined if the ischemic lesions might be 
related to aneurysm treatment.
functional outcome. Functional neurological outcome was assessed at three months after SAH using the 
modified Rankin scale (mRS). Patients lost during follow up were discarded.
Statistical analysis. All Statistical analyses were performed using Stata/IC 13.1 for Mac version. Continuous 
variables were reported as mean (standard deviation) or median (interquartile range). Metabolic records obtained 
in each hemisphere were compared with Student t-test. Level of significance was established at a p level of 0.05 
(2-sided). Sensitivity and specificity of ischemic events detected by means of CMD for DCI diagnosis were cal-
culated. In addition, a receiver operating characteristic (ROC) curve analysis was performed to determine the 
optimal cutoff value of ischemic events for the prediction of DCI.
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Results
Twenty consecutive poor grade aneurysmatic SAH patients admitted to our institution between January 2017 
and January 2019 and requiring multimodal monitoring were prospectively recruited for the study. Four patients 
were excluded: two died within the initial 24 hours and two experienced an accidental removal of the catheters 
before completing 48 hours of monitoring. The mean patients’ age was 58 years (SD:7.3). Most of the aneurysms 
were located in the anterior circulation: MCA aneurysm 38% (6/16); ACoA aneurysm 31% (5/16); Pcom aneu-
rysm 13% (2/16); Carotid aneurysm 6% (1/16); AICA aneurysm 6% (1/16) and PICA aneurysm 6% (1/16). All 
the patients were admitted in poor clinical condition, 56% (9/16) in WFNS 5. The blood assessment of the early 
CT scan revealed high amount of cisternal and intraventricular blood in most of the patients. The median (IQR) 
mFisher scale was 4 (0): 88% (14/16) mFisher:4; 6% (1/16) mFisher:3 and 6% (1/16) mFisher:2 (Table 1). Mean 
cisternal blood volume (CBV) was 22cc (SD 13.3) in the hemisphere named “a”, and 12.8cc (SD 7.10) in the con-
tralateral one. In three patients a parenchymal hematoma was additionally present. Differences in cerebral blood 
volumetry between hemispheres were inferior to 5cc in 50% of the patients.
cMD monitoring and ischemic events. Altogether, patients were monitored using bilateral CMD for 
2048 hours, consistently during the first week from SAH onset and right after the occlusion of the aneurysm. 
Mean monitoring time per patient was 108 hours (SD 45.9). A total of 323 hours (16%) were withdrawn from 
final analysis due to errors in their acquisition or processing. Out of the overall 1725 hours of bilateral obser-
vations, 15% revealed an ischemic event in at least one of the probes. Ischemic events located in hemisphere “a” 
were recorded for a total time of 188 hours (11%; 95% CI, 9.5–12.5). Meanwhile, ischemic events in the silent 
hemisphere (named “b”), were detected for 72 hours (4%; 95% CI, 3.3–5.2). During 5 hours, ischemic events were 
simultaneously detected in both catheters (Fig. 2).
Ischemic lesions not previously present in the initial CT, were identified in the follow-up MRI of 5 patients, 4 
in hemisphere “a” and 1 in hemisphere “b”. All the new infarctions detected were related with delayed ischemia 
and not attributed to the aneurysm repair procedure. Only 50% (8/16) of the patients had achieved a good 
Figure 1. (a,b) Computed tomography of a patient with a poor grade aSAH. Left posterior communicating 
aneurysm (PCom) embolized. More amount of blood in the left basal cistern of the brain. (c,d) Bilateral 
monitorization with two CMD probes. An external ventricular drainage placed on the right side and a PbtO2 
probe on the left side. The subarachnoid hemorrhage volume is represented by a red shaded area.
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functional (mRS 0–3) recovery at the three months follow-up. The median (IQR) mRS at 3 months was 3.5 (2–5). 
None of the patients initially included were lost at 3 months follow up.
Table 1 summarizes the metabolic record of every patient, including ischemic events (LPR > 40) (Fig. 3). With 
a threshold of 7 or more ischemic events, bilateral CMD monitoring strategy was able to predict the occur-
rence of delayed cerebral infarctions with high specificity (96%) and sensitivity (83%) (AUC: 0.87; 95% CI: 0.61–
1) (Fig. 4). Figure 5 shows the positive correlation observed between the hours of ischemic events and DCI 
(r = 0.841, p < 0.001). CMD samples obtained from hemispheres with incident ischemic brain lesions revealed an 
increase in the mean concentration of every metabolite but glucose when compared to unaffected hemispheres 
(Table 2).
Safety protocol. No complications directly related with the catheters were registered. Daily revisions of the 
catheter’s wounds were performed and no catheter infection was documented. Furthermore, none of the postop-
erative CT scans showed any catheter-related hemorrhage larger than 5cc.
Discussion
Cerebral infarctions are likely to occur after aneurysmal SAH. These ischemic lesions are located in territories suf-
fering angiographic vasospasms in 25–81% of cases4,13,14. The rest of brain infarctions cannot solely be explained 
by vasospasm, revealing the existence of other mechanisms of brain injury and raising the need of other diag-
nostic tools. CMD, as part of a multimodal neuromonitoring strategy, might improve delayed cerebral ischemia 
prediction. CMD offers direct metabolic information. However, this information is locally constrained and is not 
updated in real-time. Data from CMD probes is highly influenced by their location in the brain parenchyma and 
it might be misleading to extrapolate this information to interpret what is the real condition of the entire brain15. 
If SAH is considered a global cerebral disease, the location of the catheter would not be such a critical decision 
and one CMD probe might be enough to acquaint the metabolic profile of the brain as a whole. Nonetheless, as 
outlined by other authors, we believe that brain injury related to SAH may differ depending on the susceptibility 
of the different parenchymal or vascular territories16,17. Our results support this assumption proving the existence 
of infarctions in the silent or the DCI low-risk hemisphere thus providing rationale for considering bilateral CMD 
monitoring.
Subarachnoid blood volume in the initial CT after aneurysmal SAH has been defined as an independent 
prognostic factor12. Lagares et al. proved that cisternal blood volumes over 20 cc are clearly associated with an 
increased risk of poor outcome. In our series of 16 patients, the average volume of cisternal blood was 36 cc (SD: 
21.7), supporting our intention to select severely affected patients. Despite these massive volumes, in 50% of our 
patients, interhemispheric difference in blood volume was lower than 5 cc. This condition reveals how difficult 
might be to initially select which hemisphere is more exposed to delayed injury. Strategies to determine the 
Patient Age WFNS mF IPH An





(6 m)a b Total a b B LPR(a) LPR(b) B (a) (b) (a) (b)
1 63 4 4 1 MCA 25.9 9.6 35.5 47 (39.5) 7 (5.9) 0 77 (65) 1 (1) 7 (5.8) 119 1 0 PL N 4
2 72 5 4 0 PICA 26.2 25.8 52 0 1 (1.1) 0 10 (11) 2 (2.1) 0 92 0 0 N N 6
3 53 5 4 0 ACoA 2.6 2.2 4.8 0 2 (2.8) 0 0 10 (13.9) 0 72 0 0 N N 2
4 56 5 4 0 ACoA 39.4 32.8 72.2 12 (11.9) 2 (2) 0 58 (57.4) 1 (1) 1 (1) 101 1 0 PL N 6
5 55 4 2 1 MCA 2.7 1.6 4.3 74 (60) 0 0 78 (62) 0 0 124 1 0 PL N 1
6 48 4 4 0 ACoA 28.3 27.8 56.1 2 (1.5) 27 (20.5) 1 (1) 3 (2) 62 (47) 29 (23) 132 0 1 N N 6
7 66 4 3 0 MCA 24.9 2.6 27.5 0 0 0 0 0 0 11 0 0 PL N 4
8 71 4 4 0 ACoA 24.2 15.3 39.5 2 (1.4) 1 (1) 0 33 (22) 9 (6.2) 22 (15) 145 0 0 N N 2
9 63 5 4 0 ACI 16.1 19.8 35.9 0 0 0 10 (13) 0 0 77 0 0 N N 1
10 58 5 4 0 AICA 17.8 10.6 28.4 2 (1.5) 0 0 0 3 (2.2) 0 134 0 0 N N 4
11 54 5 4 1 MCA 49.8 21 70.8 0 0 0 1 (0.6) 7 (4.1) 0 172 0 0 N N 6
12 55 5 4 0 MCA 6.1 2.5 8.6 5 (4.8) 1 (1) 0 42 (41) 1 (0.9) 2 (1.9) 103 0 0 PL N 4
13 51 4 4 0 PCom 23.8 16.3 40.1 1 (1) 19 (11.9) 0 1 (0.6) 80 (0.5) 0 160 0 0 PL N 3
14 56 5 4 0 ACoA 13.3 14.6 27.9 40 (25) 0 4 (2.5) 41 (35) 0 16 (13.8) 116 1 0 N N 2
15 50 4 4 0 PCom 14.7 7.7 22.4 0 0 0 0 1 (1) 0 99 0 0 N N 1
16 51 5 4 0 MCA 20.3 15.2 35.5 0 5 (20.8) 0 1 (4) 5 (21) 0 24 0 0 N N 2
Table 1. Baseline characteristics, grading and clinical outcomes. AcoA: anterior communicating artery; ACoP: 
posterior communicating artery; AICA: anterior inferior cerebellar artery; An: Aneurysm; B: Bilateral; DCI: 
Delayed cerebral ischemia; IF: Infarction location; IPH: Intraparenchymal hemorrhage; mF: Modified Fisher 
score; MCA: middle cerebral artery; mRS: modified rankin scale; N: Normal appearing brain tissue; PICA: 
Posterior inferior cerebellar artery; PL: Perilesional brain tissue; RLP: lactate/pyruvate ratio; SAH volume: 
Subarachnoid hemorrhage volume; WFNS: World Federation of Neurosurgical Society.
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location of CMD catheters are based on the belief that the hemisphere containing the greatest volume of blood 
is the most susceptible to suffer deleterious changes. Tholance et al. developed an algorithm to determine the 
optimal location of CMD catheters in order to early detect DCI occurrence18. They improved the detection of 
DCI from 54% when the catheter was implanted in the hemisphere with more blood, to 79% when implementing 
this algorithm instead18. According to these authors, CMD catheters should be placed in the ACA territory for 
Anterior communicating artery (ACom) aneurysms and in the ipsilateral hemisphere for Middle cerebral artery 
(MCA), Internal carotid artery (ICA) and Posterior communicating artery (PCom) aneurysms. Nonetheless this 
algorithm failed to detect at least 20% of DCI. They also noted that territories where DCI was found had previ-
ously shown high LPR values. This finding supports the relevance of local measures in SAH. Our results concur 
with these statements, since CMD catheters from areas developing DCI showed clear differences compared to 
those located in areas which did not show any delayed brain injury.
In this clinical research, ischemic events were defined by validated values of LPR and Glucose7,19. Given the 
scarce therapeutic strategies to prevent DCI, we prioritized CMD to be specific, thus we used a restrictive defini-
tion of ischemia. Other scenarios deemed to increase the sensibility of CMD to predict DCI such as mitochondrial 
dysfunction (Increase in LPR, depending on Lactate with normal or increased pyruvate) or LPR augmentation 
without glucose decrease, were not considered20. Importantly, our LPR values were comparable to those detailed 
by other authors in critical patients11,17.
CMD has consistently proven its ability to display metabolic changes in different areas surrounding a focal 
concussion in the setting of traumatic brain injury (TBI)21. Therefore, a rationale exists for the use of multiple 
CMD catheters in patients suffering TBI22. However, this practice has not been established nor generalized in 
SAH. Jacobsen et al. recently reported their experience with multiple CMD catheters in SAH patients; nonethe-
less, only one hemisphere was monitored, and the detection of contralateral infarctions was not assessed20. Unlike 
TBI, diffuse and bilateral delayed infarctions in SAH are rare and probably the result of severe ischemic damage 
taking place within the very first hours. Hence, global DCI might be present in terminal SAH patients without 
any chance of therapeutic intervention23. Our results support the singularity of diffuse ischemia in SAH, since 
synchronic bilateral metabolic ischemic events hardly occurred for 5 hours. Therefore, if global infarction in SAH 
is that rare, the metabolic changes registered with one catheter should be extrapolated to the rest of the brain with 
extreme caution. The high efficiency of CMD measuring local changes in brain metabolism could be properly 
extrapolated if multiple catheters would be implemented15. In 5 out of 16 patients (31.25%) we observed cerebral 
infarctions, in one of them in a pre-considered silent territory. Herein CMD proved its high sensitivity predicting 
DCI, since every established infarction was preceded by various records of ischemic metabolism.
Our bilateral CMD monitoring strategy allowed us to detect that out of the total of ischemic events, 24% 
occurred in pre-considered silent hemispheres (b). These ischemic events came with few or no changes in the 
contralateral hemisphere (a). These findings match with the current evidence that defends that brain infarctions 
Figure 2. Flow diagram summarizing bilateral hours of monitorization in the study. I.E: Ischemic events; h: 
total hours of bilateral monitorization; DCI: Delayed cerebral infarction.
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also occur in silent territories6. However, the majority of ischemic events do not lead to DCI, either because they 
do not last long enough or in response to the implementation of therapeutic measures that prevent infarction 
from being established. Nonetheless, some patients unavoidably develop permanent ischemic lesions despite 
of specific therapeutic attempts. Several studies have conferred CMD a high positive predictive value on DCI 
prediction18. In our series, CMD demonstrated a sensitivity and specificity of 96% and 83% respectively, when a 
threshold of 7 or more ischemic events was used. Despite the small size of our sample, these results are equal or 
superior to those reported by other authors17,18.
Summarizing, herein we have exposed a novel neuromonitoring strategy for SAH based on the bilateral use 
of CMD probes. This strategy allowed translating focal data into global metabolic trends in the brain. As stated 
in previous reports, CMD proved to be safe and useful. None of our patients suffered infections nor significative 
hemorrhages (<5 mm3) related to probe implantation. Furthermore, our results show that metabolic deficits 
detected by CMD rarely occur simultaneously and globally in SAH, affecting non-synchronously different brain 
territories. Nevertheless, risk-benefit balance should be carefully regarded since the rather small individual risk 
of implantation of multiple probes might occur, resulting in life threatening complications.
This study is not without limitations. It is important to note that this outstanding performance of CMD in our 
series might be due to a selection bias, since all the patients were severely affected by SAH (WFNS grades 4 and 
5). Hence, it is expected that CMD predictive value would decrease in a more heterogeneous sample of patients. 
Figure 3. Timeline recordings for patients 1, 4, 5, 6 and 14. The periods in which metabolic ischemic events 
were registered are represented by a blue shade.
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Another limitation of this study worth mentioning is the need to deepen the prediction of bilateral CMD moni-
toring in the case of posterior circulation aneurysms. A future cohort of patients with posterior fossa aneurysms 
may be necessary to determine the utility of these resources in these selected patients. Finally, despite obtaining 
sound statistically significant results, the limited number of patients calls for cautious interpretation. Our findings 
represent an intriguing starting point for further research but might not justify bilateral monitoring on their own.
conclusion
In selected SAH patients, bilateral CMD catheters seem to be safe and potentially useful to predict ischemic 
events that would have remained undiagnosed with a unilateral strategy. Almost a quarter of metabolic crisis 
patterns would have been silent if only one hemisphere had been monitored. Actually, less than 1% of ischemic 
events occurred simultaneously in both hemispheres. These findings suggest that careful extrapolation of data 
Figure 4. ROC and AUC analyses for bilateral monitorization and DCI prediction.
Figure 5. Correlation between hours of ischemic events and MRI infarctions (DCI). Pearson’s bivariate 
correlation coefficient (r).
Parameter All No DCI Hemisphere DCI Hemisphere P Value
Glucose (mmol/L) 1.62 (1.58–1.66) 1.79 (1.74–1.83) 0.87 (0.82–0.92) <0.001
Lactate (mmol/L) 3.94 (3.85–4.03) 3.42 (3.34–3.50) 6.29 (5.99–6.59) <0.001
Pyruvate (μmol/L) 115.67 (113.57–117) 113.187 (111.05–115) 126.86 (120.49–133) <0.001
Glycerol (μmol/L) 323.3 (310.91–335) 254.26 (243.25–265) 634.2 (594.70–674) <0.001
Ratio L/P 37.76 (34.91–40.6) 28.46 (27.15–29.7) 79.68 (65.51–93.8) <0.001
Table 2. Average biochemical parameters observed in the sample, and breakdown by DCI hemispheres and 
No-DCI hemispheres. The p-value refers to the difference between DCI and No-DCI hemispheres.
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from unilateral monitoring should be considered. In the absence of effective focal therapies, adhering to locally 
constrained measurements may mislead our therapeutic decisions resulting in harmful consequences for the 
unmonitored brain.
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